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Malaria is an infectious disease that affects mil-
lions of people in tropical and sub-tropical regions of the 
world. According to the estimates of the World Health 
Organization (WHO), 40% of the world population, that 
is, 3.3 billion people, live at high risk of contracting this 
disease in the 106 countries where malaria is considered 
to be endemic. In 2009, 225 million cases of malaria were 
registered around the world and caused approximately 
one million deaths, of which 90% were among African 
children less than five years of age (WHO 2010). In the 
Brazilian Amazon, this disease is still a grave problem 
for public health authorities due to its high incidence and 
the debilitating effects on people suffering from this dis-
ease. This disease is believed to negatively influence the 
potential economic development of this region (Oliveira-
Ferreira et al. 2010).
Resistance of the human malaria parasite Plasmodi-
um falciparum Welch to antimalarial drugs has emerged 
as one of the greatest challenges to the control of malaria. 
Drug resistance has led to increased mortality in hyper 
and holoendemic areas and contributed to the appear-
ance and spread of new focal areas of malaria caused by 
P. falciparum. Furthermore, resistance has been identi-
fied as a factor that economically compromises malaria 
control efforts (Trape et al. 2002). Great effort and time 
have been dedicated to the in vitro reproduction of the 
erythrocytic stages of the Plasmodium life cycle as a 
fundamental tool for studying the mechanisms of sus-
ceptibility and resistance to drugs as well as screening 
for the identification of new drugs (Girard et al. 2007). 
Several natural products have been revealed as 
promising sources of antimalarial compounds. Tradi-
tional knowledge of the usefulness of medicinal plants 
has led to the isolation and identification of the antima-
larial compounds quinine and artemisinin, which are 
currently in use and which are isolated from species of 
Cinchona L. (Rubiaceae) and the leaves of Artemisia an-
nua L. (Asteraceae), respectively (Vale et al. 2005).
A. annua is a plant native to North China, mainly in 
the provinces of Chahar and Suiyuan, where it is known 
by the common name qinghao (blue-green hao) (Hsu 
2006). This herb has been used in traditional Chinese 
medicine for more than 2,000 years as an infusion for 
the treatment of fever and malaria. The modern Chinese 
Pharmacopeia describes the dry leaves of this plant as 
a medicine for fever, including malaria (Mueller et al. 
2000). Chinese researchers have studied more than 30 
species belonging to the genus Artemisia in the search 
for potential antimalarial activity; however, only A. an-
nua and Artemisia apiacea Hance have proven to be 
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Artemisinin is the active antimalarial compound obtained from the leaves of Artemisia annua L. Artemisinin, and 
its semi-synthetic derivatives, are the main drugs used to treat multi-drug-resistant Plasmodium falciparum (one of 
the human malaria parasite species). The in vitro susceptibility of P. falciparum K1 and 3d7 strains and field iso-
lates from the state of Amazonas, Brazil, to A. annua infusions (5 g dry leaves in 1 L of boiling water) and the drug 
standards chloroquine, quinine and artemisinin were evaluated. The A. annua used was cultivated in three Amazon 
ecosystems (várzea, terra preta de índio and terra firme) and in the city of Paulínia, state of São Paulo, Brazil. Ar-
temisinin levels in the A. annua leaves used were 0.90-1.13% (m/m). The concentration of artemisinin in the infusions 
was 40-46 mg/L. Field P. falciparum isolates were resistant to chloroquine and sensitive to quinine and artemisinin. 
The average 50% inhibition concentration values for A. annua infusions against field isolates were 0.11-0.14 μL/mL 
(these infusions exhibited artemisinin concentrations of 4.7-5.6 ng/mL) and were active in vitro against P. falciparum 
due to their artemisinin concentration. No synergistic effect was observed for artemisinin in the infusions.
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effective against P. falciparum and Plasmodium vivax 
Grassi & Feletti (Rodrigues et al. 2006). Among the sec-
ondary metabolites present in A. annua, artemisinin is 
considered to be the principle antimalarial component. 
Artemisinin levels vary considerably depending upon 
the part of the plant, cultivation conditions and seasonal 
and geographical variations. High levels of artemisinin 
are found in the leaves and flowering parts, especially 
in the period immediately before flowering (0.01-1.40%) 
(Baraldi et al. 2008). Most of this variation is attribut-
ed to genetic factors; however, even high-artemisinin-
yielding varieties may have their artemisinin production 
reduced due to the influence of environmental condi-
tions. Altitude, latitude, soil nutrients and pH, the length 
of day (photoperiod), flowering time, drying time and 
storage conditions determine the artemisinin content in 
the plant (Wilcox et al. 2004, Ferreira et al. 2005). 
 The global demand for artemisinin and its derivatives 
increased from 11.2 million treatments in 2005 to approx-
imately 158 million in 2009. The cost-benefit relation-
ship represents the greatest problem for the viability of 
the synthesis of artemisinin. The isolation of artemisinin 
from the leaves of A. annua is the best method for obtain-
ing artemisinin, from which semi-synthetic derivatives 
such as artesunate, artemether and arteether are prepared 
(WHO 2010). Given the possible decrease in the supply 
of artemisinin caused by this increase in world demand, 
the cultivation of A. annua, especially in endemic areas, 
may be an important alternative for the production of 
artemisinin-based drugs (Mueller et al. 2000). This plant 
was introduced in Brazil in the 1980’s and has been the 
subject of constant study and attempts at genetic improve-
ment through traditional methods. These studies resulted 
in the selection of high-artemisinin-yielding genotypes 
for cultivation in intertropical regions (Magalhães et al. 
1997). Although trials with some of these genotypes have 
already been conducted in the Brazilian Amazon Region, 
it is necessary to perform multidisciplinary research on 
the genetic selection and improvement of A. annua for 
cultivation in distinct Amazon ecosystems.
Infusion is the pharmaceutical form indicated in the 
Chinese Pharmacopeia for A. annua and is the most com-
monly used form today. The recommended dose varies 
from 4-9 g of dried leaves for each litre of boiling water 
(Ridder et al. 2008). In the most important clinical studies 
reported in the literature involving infusions of A. annua, 
5-9 g of dry plant per litre of boiling water per day for 
five-seven days has been the usual course of treatment. In 
clinical studies, the therapeutic efficiency of A. annua in-
fusions was up to 70%, but high recrudescence rates were 
reported, which led the authors of these clinical studies to 
not recommend the use of A. annua infusions as a mono-
therapy (Mueller et al. 2000, 2004, Räth et al. 2004).
At present, A. annua is being cultivated in Amazon 
ecosystems through the Artemisia Project, which is be-
ing financed by a grant from the Brazilian Government’s 
National Malaria Network. The evaluation of the quality 
of these hybrids has been performed by monitoring bio-
mass during the plant’s life cycle, as well as the evalu-
ation of artemisinin levels in the leaves. In the present 
study, the susceptibility of field isolates of P. falciparum 
from the Brazilian Amazon to A. annua infusions was 
evaluated. The A. annua used in this study was culti-
vated in the várzea, terra firme and terra preta de ín-
dio ecosystems. An attempt was made to understand the 
interaction between the parasites and the infusions and 
ultimately to establish the antiplasmodial activity of the 
infusions against P. falciparum in vitro as a parameter in 
the evaluation of the potency of cultivated A. annua and 
the infusions made from the cultivated plant.
SUBJECTS, MATERIALS AND METHODS
Plant material - The A. annua L. used in this study 
was grown from seed in greenhouses and then cultivated 
in várzea, terra firme and terra preta de índio Amazoni-
an ecosystems in the experimental areas of the Brazilian 
Agriculture and Animal Husbandry Research Company 
(Embrapa) in Manaus, state of Amazonas, Brazil. Plant 
collection was performed in June 2008 from these three 
Amazonian ecosystems. A hybrid of A. annua from the 
Multidisciplinary Centre for Chemical, Biological and 
Agricultural Research (CPQBA) of the State University 
of Campinas (UNICAMP), Paulínia, state of São Paulo, 
Brazil, was also used for reference and was collected in 
March 2008. Reference plant materials (vouchers) are 
available at CPQBA and Embrapa and live plant speci-
mens are maintained in continuous culture on a yearly 
basis at these institutions. For this study, the aerial parts 
of the plants were harvested immediately before flower-
ing commenced and dried in an oven at 40ºC.
Preparation of leaf infusions - Infusions of A. annua 
leaves from plants grown in terra firme, várzea and terra 
preta de índio areas at Embrapa in Manaus and at CPQBA 
in Paulínia were prepared by combining 5.0 g of dry, 
ground leaves and 1.0 L boiling distilled water. The mix-
ture was covered and left for 15 min and then filtered hot.
Preparation of leaf extracts for quantification of ar-
temisinin - Toluene (10.0 mL) was added to dried leaves 
(200 mg) and this mixture was subjected to extraction in 
an Ultra-Turrax homogeniser (IKA, Guankzhou, China) 
for 30 s. The resulting suspension was centrifuged for 6 
min at 3,200 rpm (1,720 g). The supernatant solution was 
used in the analyses as described below.
Determination of artemisinin in toluene solutions 
and infusions of A. annua leaves - Artemisinin levels 
were determined in dry A. annua leaf samples and in-
fusions using thin-layer chromatography (TLC)-photo-
densitometry as previously described (Marchese et al. 
2001) with slight modifications. After the centrifugation 
step described above, the supernatant toluene solution 
(3.0 μL) was applied in duplicate to a commercial alumin-
ium-backed silica gel TLC plate (Merck). On the same 
plate, four different volumes (1.5-3.0 μL) of a standard 
solution of artemisinin (0.25 mg/mL) in methanol were 
applied to the TLC plate as calibration points. The TLC 
plate was eluted with a 98.5:1.5 mixture of chloroform 
and methanol. The average elution times were 4 ± 1 min. 
The eluted TLC plate was sprayed with p-anisaldehyde 
solution [0.5 mL p-methoxybenzaldehyde, 10 mL glacial 
acetic acid, 85 mL ethanol and 5 mL concentrated sul-
phuric acid (95-97%)] and heated for 6 min at 100ºC. 
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Next, the TLC plate was scanned using a photodensitom-
eter (GE Healthcare Image Scanner®). The optical densi-
ties of the artemisinin spots in the toluene solutions were 
compared to the optical densities of the standard samples 
of artemisinin (external calibration) using GE Image 
Quant TL® software (GE Healthcare, Uppsala, Sweden). 
To quantify artemisinin in the infusions, 100 mL of 
each infusion was totally evaporated under vacuum (ca. 
25 mmHg) using a rotary evaporator and a bath tempera-
ture of 38ºC. The resulting dry extract was suspended in 
10.0 mL of methanol, which was measured using a volu-
metric pipette. A total of 3.0 μL of this suspension was 
applied to a TLC plate using a gas-tight microsyringe and 
evaluated as described above for toluene solutions.
Continuous culture of P. falciparum - The strains 
used in this study were the antimalarial drug-suscepti-
ble 3D7 clone of the NF54 isolate (unknown origin) and 
the chloroquine-resistant, pyrimethamine-resistant and 
cycloguanil-resistant K1 strain (Thailand). Strains were 
acquired from MR4 (Malaria Research and Reference 
Reagent Resource Center, Manassas, VA, USA). Addi-
tionally, nine P. falciparum field isolates (representative 
genotypes from the Brazilian Amazon Region) were ob-
tained from symptomatic malaria patients who present-
ed themselves for diagnosis and treatment at the Heitor 
Vieira Dourado Tropical Medicine Foundation (FMT-
HVD), Manaus. Whole blood samples were processed 
as described elsewhere (Vieira et al. 2004) and infected 
erythrocytes were directly added to complete RPMI-me-
dium and put in plastic flasks for in vitro culture (with-
out cryopreservation) under a low-oxygen atmosphere. 
Patients presenting clinical symptoms related to severe 
malaria were invited to be enrolled in this study after 
confirmation of P. falciparum mono infection by thick 
smear diagnosis and their signing of an informed consent 
form (FMT-HVD Ethics in Research Commission 1838). 
Parasites were maintained in continuous culture using the 
method of Träger and Jensen (1976) with modifications, 
as described in Andrade-Neto et al. (2007), using type A+ 
human erythrocytes in RPMI-1640 medium (Sigma-Al-
drich, St. Louis, MO, USA) supplemented with 10% A+ 
human plasma (donated by blood banks). Cultures were 
maintained under an environment of 5% O2, 5% CO2 and 
90% N2 and incubated at 37ºC. When cultures attained a 
parasitaemia level of 4-5%, they were synchronised with 
5% sorbitol (Lambros & Vanderberg 1979).
In vitro susceptibility test - Infusions of A. annua, as 
prepared above, were diluted by a factor of 1:10 and then 
serially diluted in RPMI-1640 culture medium by a fac-
tor of 1:5 to produce seven diluted samples with overall 
dilutions that ranged from 1:10-1:1.5 × 105. These dilute 
samples were tested in vitro against field isolates and 
standard strains of P. falciparum. The commercial drug 
standards chloroquine diphosphate salt (Sigma-Aldrich, 
Steinheim, Westphalia, Germany), quinine sulphate salt 
(Sigma-Aldrich, Steinheim, Westphalia, Germany) and 
artemisinin (Sigma-Aldrich, Steinheim, Westphalia, Ger-
many) were also tested in the concentration ranges of 2.5 
× 103-3.4, 5.0 × 102-0.70 and 1.0 × 102-6.4 × 10-3 ng/mL, 
respectively. The microtest was performed according to 
the method of Rieckmann et al. (1978) with modifica-
tions as described in Andrade-Neto et al. (2007). Briefly, 
the wells of a 96-well test plate were loaded with 180 μL 
of a parasitised red blood cell suspension in culture me-
dium containing predominantly young trophozoites (ring 
forms), a 3% haematocrit and 1.5% initial parasitaemia. 
Then, 20 μL of a commercial drug solution or a dilute in-
fusion was added to wells for a final volume of 200 μL per 
well. Each test was performed in triplicate. Wells contain-
ing only parasitised red blood cells in complete culture 
medium (RPMI-1640 plus 10% human serum) were used 
as negative controls of parasite growth. Each test plate 
was incubated for 48 h at 37ºC and at low O2 tension in an 
acrylic, gas-tight chamber in an incubator. After incuba-
tion, thin blood smears were prepared from the contents 
of each well. Blood smears were dyed with Panótico® 
(Laborclin, Pinhais, Paraná, Brazil) and examined under 
an optical microscope. The number of parasites present in 
a total of 2,000 red blood cells was counted. Parasitaemia 
levels were expressed as a percentage. 
Data analysis - The parasitaemia levels of the test 
wells were compared with those of the control wells to 
evaluate parasite growth in the presence of diluted A. 
annua infusion or drug standards. The inhibition of 
parasite growth was evaluated as the difference in the 
average level of parasitaemia of triplicate negative con-
trol wells and the average parasitaemia level of the trip-
licate wells of a given test sample and was expressed 
as a percentage (I%) by dividing this difference by the 
average negative control parasitaemia level [I% = (avg 
parasitaemia of control - avg parasitaemia of sample) 
÷ avg parasitaemia of control]. The median inhibition 
concentration (IC50) and the standard deviation with a 
95% confidence interval were calculated based on lin-
ear regression analysis using Microcal Origin® software 
(OriginLab, Northampton, Massachusetts, USA).
RESULTS
The dried leaves of A. annua hybrids cultivated in 
the várzea, terra preta de índio and terra firme Ama-
zonian ecosystems exhibited high levels of the antima-
larial natural product artemisinin. The results from our 
TLC-photodensitometric analysis indicate that artemisi-
nin levels in dry leaves ranged from 0.90 ± 0.10%-1.10 
± 0.07% (Table I). The dry leaves of the standardised 
plant cultivated in Paulínia exhibited artemisinin levels 
of 1.13 ± 0.05%. The seeds were obtained from these 
standardised plants, which in turn gave rise to the plants 
cultivated in the Amazon.
The concentration of artemisinin in infusions of 
leaves of cultivated A. annua ranged from 40-46 mg/L 
(Table I). Thus, we did not observe a large variation in 
the concentration of artemisinin in the infusions. Stan-
dardised A. annua cultivated in Paulínia exhibited higher 
levels of artemisinin in its leaves and in its leaf infusions. 
The efficiency of artemisinin extraction by the infusion 
of leaves in boiling water ranged from 78-91% for plants 
cultivated in terra preta de índio and terra firme plots. 
The efficiency of extraction described here refers to the 
percentage of the total artemisinin present in the leaf 
sample that was present in the final infusions.
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The drug sensitivity profiles of the nine P. falci-
parum field isolates were evaluated against the com-
mercial drugs chloroquine, quinine and artemisinin 
through the determination of their IC50 values (Table 
II). For chloroquine, the average IC50 value for the nine 
field isolates was 268 ± 129 nM. The lowest of the IC50 
values for these parasites was 166 nM. Thus, all field 
isolates were considered resistant to chloroquine (WHO 
2007). For quinine, the average IC50 value for the nine 
field isolates was 174 ± 40 nM (the absolute range of 
IC50 values was 110-259 nM), as shown in Table II. All 
P. falciparum field isolates were considered sensitive 
to quinine because their IC50 values were lower than the 
in vitro threshold values (IC50 = 500 nM) for quinine re-
sistance established by the WHO (2007). Artemisinin 
was highly active against Amazonian field isolates of 
P. falciparum. The IC50 values obtained for artemisinin 
against Amazonian field isolates exhibited low varia-
tion (average IC50 = 2.1 ± 1.0 nM). Given the number 
of samples studied, the levels of sensitivity of Amazo-
nian P. falciparum field isolates to artemisinin are in 
agreement with results for other field isolates reported 
in the literature (Jambou et al. 2005, Ferreira et al. 2007, 
2008, Gama et al. 2011). In Fig. 1, concentration-response 
curves are presented for the largest and smallest inhibi-
tion concentrations obtained for field isolates against 
chloroquine, quinine and artemisinin. These curves are 
generally representative of the experimental observations 
made on the rest of the field isolates.
The susceptibilities of 11 samples of P. falciparum 
(2 standard and 9 field isolated samples) to infusions of 
A. annua leaves from three Amazonian ecosystems and 
Paulínia were evaluated herein. Immediately after prep-
aration, each infusion was diluted and applied directly to 
the microtest plate without any prior treatment. The IC50 
values were calculated in experimentally relevant units 
of microlitres of infusion per millilitre (µL/mL) of total 
solution in each microplate well. The average IC50 val-
ues of the A. annua leaf infusions against samples of P. 
falciparum were 0.11 ± 0.03, 0.11 ± 0.02, 0.13 ± 0.1 and 
0.14 ± 0.04 μL/mL for plants cultivated in Paulínia, terra 
preta de índio, terra firme and várzea, respectively. If 
the data from the TLC-photodensitometric analysis of 
the infusions are taken into account, these diluted infu-
sions that produced the IC50 values contain 5.1, 4.7, 5.3 
and 5.6 ng/mL of artemisinin, respectively. There was 
no significant difference in the IC50 values of plant infu-
sions from different regions/ecosystems against individ-
ual field isolates of P. falciparum. Similarly, there was 
no significant difference in the susceptibility profiles 
among the field isolates to individual infusions. In Fig. 
2, the concentration-response curves are presented for 
a field isolate against different infusions of A. annua. 
In general, these curves are representative of the behav-
iour profile of field isolates of P. falciparum in the pres-
ence of A. annua infusions. The biological responses of 
this field isolate to the leaf infusions of plants cultivated 
in terra firme and várzea areas were slightly delayed, 
which resulted in higher IC50 values.
DISCUSSION
The great importance attributed to A. annua after the 
discovery of the highly active antimalarial compound in 
the leaves of this plant led to the intensive collection and 
decimation of the plant in certain regions of the world. 
TABLE I
Data on artemisinin in leaves and infusions
Plant origin
Artemisinin
in dry leaves 
(m/m)
Concentration of 
artemisinin 
in infusions 
(mg/L)
Efficiency of 
extractiona 
Paulínia 1.13 ± 0.05 46 ± 2 81
Terra preta 1.10 ± 0.07 43 ± 1 78
Terra firme 0.90 ± 0.10 41 ± 2 91
Várzea 0.90 ± 0.10 40 ± 1 90
a: percentage of artemisinin extracted from leaves into tea 
preparation. Artemisinin levels in dry leaves and infusions 
prepared from Artemisia annua cultivated in three Amazo-
nian ecosystems (Manaus, state of Amazonas) and Paulínia 
(state of São Paulo) and artemisinin extraction efficiency of 
infusion procedure.
TABLE II
Antiplasmodial activity of drugs
Drug
Median inhibition concentrations (IC50) (nM)
Amazon field isolates Standard strains
Mean
(n = 9) Lowest/highest K1 3D7
Chloroquine diphosphate 268 166/460 136 ± 10 60 ± 6
Quinine sulphate 174 110/259 160 ± 8 110 ± 10
Artemisinin 2.1 0.9/3.5 2.9 ± 1 1.7 ± 1
IC50 values for commercial drugs chloroquine, quinine and artemisinin against standard strains and Amazonian field isolates of 
Plasmodium falciparum.
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As a response to the high demand for this plant, A. an-
nua has been planted on a large scale in China, Vietnam, 
Turkey, Iran, Afghanistan and Australia, as well as some 
countries in Europe and the Americas (Bhakuni et al. 
2001). Faced with a possible shortage in the supply of ar-
temisinin caused by the increase in demand, the cultiva-
tion of A. annua in endemic areas should be considered a 
viable alternative that will guarantee an adequate supply 
of plant materials and production of the drug artemisinin 
(Ridder et al. 2008). The present study demonstrated that 
A. annua cultivated in three types of representative soils 
of the Amazon Region possesses a high level of artemisi-
nin. This finding, together with agronomic and biomass 
data, support the notion that A. annua can be cultivated 
in this rainy, humid equatorial region. The A. annua hy-
brid cultivated in Paulínia (UNICAMP/CPQBA) is con-
sidered stable because it has been cultivated for many 
generations and has had its ideal growth conditions es-
tablished for some time. Previous studies have reported 
that leaves of this hybrid have artemisinin levels in the 
range 0.8-1.2% (Magalhães et al. 1997, Marchese et al. 
2001). No large variation in the levels of artemisinin 
among the hybrids in the three Amazonian ecosystems 
was observed despite the rather large differences in the 
nutritional composition of soils of the várzea, terra preta 
de índio and terra firme areas (Sanchez et al. 1982). The 
levels of artemisinin found in these hybrids cultivated 
in the Amazon are similar to those found in the stan-
dardised and stabilised plants from Paulínia from which 
the Amazon hybrids are derived. The plants used in this 
study are the result of the first generation of A. annua 
cultivated in these Amazonian soils and these plants are 
still going through a process of adaptation to the climatic 
and geologic conditions of the Amazon Region.
The method used to determine the levels of artemisinin 
in the dry leaves and infusions prepared from these leaves 
is semi-quantitative and is based on TLC-photodensi-
tometry, which has a high correlation with the method of 
choice, namely, high-performance liquid chromatography 
(Marchese et al. 2001). TLC-photodensitometry is rapid 
because 3-4 samples and calibration samples are simul-
taneously eluted and quantified by the software, which 
has as its input the high-resolution scan of the eluted TLC 
plate. Furthermore, TLC-photodensitometry is very low 
cost and is highly adaptable to field conditions, where it is 
useful in the processing of a large number samples during 
the process of plant selection for genetic improvements. 
This method was also used to measure artemisinin levels 
in previous studies that evaluated the biological activity of 
A. annua infusions (Atemnkeng et al. 2009). 
Fig. 1: concentration-response curves for field isolates of P. falci-
parum in the presence of various concentrations of commercial drug 
standards (A: chloroquine; B: quinine; C: artemisinin) (lowest and 
highest IC50 values). Asterisk means relative growth of P. falciparum 
= avg % parasitaemia of test (sample) wells/avg % parasitaemia of 
untreated control wells (95% confidence interval). Statistical analysis 
among additional assays: standard error = 0.0007; p = 0.10.
Fig. 2: concentration-response curves for a field isolate of P. falci-
parum in the presence of various concentrations of infusions of Ar-
temisia annua from different ecosystems/regions. Asterisk means 
relative growth of P. falciparum = avg % parasitaemia of test (sample) 
wells/avg % parasitaemia of untreated control wells (95% confidence 
interval). Statistical analysis among additional assays: standard error 
= 0.0006; p = 0.10.
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Pure artemisinin has poor solubility in water and, 
as was shown above, infusions of the dry leaves of A. 
annua prepared as recommended in the Chinese Phar-
macopeia contain a substantial quantity of artemisinin 
(Table I). These findings are similar to those found by 
Räth et al. (2004), who performed a pharmacokinetic 
study utilising an infusion of A. annua to determine 
the plasma concentration of artemisinin after the oral 
administration of the infusion. In the study by Räth et 
al. (2004), the leaf infusion was prepared in a way that 
was analogous to that used in the present study start-
ing from dry leaves with 1.39% artemisinin and yield-
ing infusions with 57.5 mg artemisinin/L. Atemnkeng 
et al. (2009) used this procedure to prepare infusions 
containing 34 mg artemisinin/L from dry leaves that 
contained 1.12% artemisinin. Despite the low solubility 
of artemisinin in water, the large quantities of the drug 
in infusions is believed to be due to the presence of 
other extracted constituents of the plant that have am-
phiphilic properties (e.g., flavonoids and/or saponins), 
which increase the solubility of artemisinin in water 
(Ridder et al. 2008). 
During the adaptation of medicinal plants to new cli-
matic and geologic conditions, it is important to accom-
pany the process with techniques that will guarantee the 
quality of the plant material obtained, such as the moni-
toring of the levels of active compounds which is a com-
mon practice. For the quality control of cultivated A. an-
nua, the determination of artemisinin levels in the leaves 
is crucial (Celeghini et al. 2006). In the present study, the 
quality of the A. annua hybrids cultivated in the Brazil-
ian Amazon was monitored to establish artemisinin lev-
els in the leaves through extraction with the low-polarity 
solvent toluene. The leaves of the hybrids cultivated in 
the Amazonian ecosystems contained acceptable levels 
of artemisinin: however, the standardised A. annua hy-
brids from CPQBA (Paulínia) had the highest levels of 
artemisinin. The quality of the infusions prepared from 
the leaves of the Amazonian hybrids was also monitored 
and compared with the standardised plant from Paulínia 
through the levels of artemisinin in the infusions and by 
testing these infusions for antimalarial activity against P. 
falciparum in vitro. There are reports in the literature on 
the in vivo antimalarial activity, pharmacology, efficacy 
and safety of A. annua infusions in human clinical trials 
(Mueller et al. 2000, 2004, Räth et al. 2004) and in vivo 
in animals using rodent malaria parasite-based models 
(Atemnkeng et al. 2009). However, we could find no pre-
vious report on the in vitro antiplasmodial activity of A. 
annua infusions. In a recent study, the cytotoxicity of A. 
annua infusions was assessed by determining cellular 
viability using the (2-methoxy-4-nitro-5-sulphophenyl)-
2H-tetrazolium-5-carboxanilide assay. In that study, the 
viability of cells in the presence of different concentra-
tions of A. annua infusion was above 72% even when the 
highest concentrations were tested (Oliveira et al. 2009). 
These data are consistent with the generally low cyto-
toxicity of A. annua infusions.
The stabilisation of geographically specific popu-
lations of P. falciparum in continuous culture permits 
the evaluation of the actual susceptibility profiles to 
drugs and to natural products of the parasites that are 
in circulation in the human (and insect) populations in a 
given region (Andrade-Neto et al. 2007). In the present 
study, it was possible to stabilise, in continuous culture, 
nine (16%) of 55 field isolates of P. falciparum. The 
increase in the therapeutic failure rates of many anti-
malarial drugs in most malarious regions requires epi-
demiologic monitoring and monitoring of the dynamics 
of drug resistance. Information on the epidemiology of 
resistance can be applied to the monitoring and control 
of the appearance and propagation of chemoresistance 
in populations of natural parasites. This monitoring 
can be performed with drugs in use in a particular lo-
cation or with new drug alternatives, especially when 
the parasite exhibits cross-resistance to drugs (Ferreira 
et al. 2007, Chiyaka et al. 2009). The stabilised field 
isolates developed and examined in the present study 
exhibited similar sensitivity profiles to chloroquine, 
quinine and artemisinin. The resistance of Amazonian 
P. falciparum to chloroquine in vitro was expected giv-
en that this parasite is generally known to be resistant 
to this drug throughout the Amazon and many other 
parts of the world. In general, chloroquine is no longer 
recommended for the treatment of P. falciparum infec-
tions due to the high levels of resistance observed in 
the clinical setting (WHO 2005). Although there are re-
ports on the in vivo and in vitro resistance to quinine in 
the Amazon Region (Alecrim 1981), in the present work 
resistance to quinine was not detected. However, two 
samples revealed high IC50 values (224 and 259 nM) that 
were lower than the in vitro threshold value for quinine 
resistance (500 nM) established by the WHO (2007). 
The levels of field isolate parasite inhibition (IC50 = 2.1 
± 1.0 nM) by artemisinin are generally in agreement 
with data from other parts of South America and Bra-
zil (Jambou et al. 2005, Ferreira et al. 2007, 2008). The 
drug susceptibility of field isolates was evaluated as a 
means to characterise the resistance profiles of the sam-
ples of Amazonian parasites utilised to evaluate their 
susceptibility to infusions.
The samples of P. falciparum evaluated in this study 
exhibited a high degree of susceptibility to infusions 
prepared from the dry leaves of A. annua cultivated in 
all ecosystems. Even highly dilute infusions (1:6.2 × 
103; effective concentrations of artemisinin of ca. 6.4 
ng/mL) inhibited up to 100% of parasite growth in al-
most all of the field isolates (data not shown). The IC50 
values of the infusions were as low as 0.11 ± 0.02 μL/
mL. Based on our TLC-photodensitometry studies, 
this value corresponds to an effective artemisinin con-
centration in the experimental test wells of 4.7 ng/mL. 
These IC50 values were observed for infusions prepared 
from the leaves of A. annua cultivated in the terra preta 
ecosystem. IC50 values obtained in the in vitro tests in-
volving infusions were comparable (Table III). Similar 
levels of artemisinin in the A. annua plants cultivated in 
the different soils of the Amazon and Paulínia (Table I) 
were found. Also, similar concentrations of artemisinin 
were detected in the infusions prepared from the leaves 
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of A. annua. In addition, pure artemisinin was generally 
quite active in vitro against all parasites used in this 
study, as evidenced by the IC50 values (Table II). It is im-
portant to develop high-artemisinin-yielding genotypes 
of A. annua, especially in endemic areas, where such 
plants may be a means by which to guarantee a constant 
supply of plant material for artemisinin production. 
However, according to previous in vitro studies on the 
active components of A. annua against P. falciparum, 
artemisinin is not the only active substance present in 
the plant. It has been demonstrated previously that fla-
vonoids present in A. annua are also involved in the in 
vitro antiplasmodial effect of artemisinin. These fla-
vonoids have little antiplasmodial activity themselves, 
but are capable of acting in synergy with artemisinin 
(Willcox et al. 2004, Bilia et al. 2006). This result indi-
cates that the evaluation of the in vitro antiplasmodial 
activity of infusions prepared from plants whose adap-
tation is underway can be an important tool to monitor 
and guarantee the activity and stability of A. annua. It is 
noteworthy that in the data generated herein, there was 
no evidence for in vitro synergistic effects.
As stated above, the plants in the present study are 
first-generation A. annua cultivated in the Amazon. De-
spite the relatively high yield of artemisinin detected in 
leaves and the high antiplasmodial activity detected in 
the in vitro assay (as evidenced by the low IC50 values 
of all infusions against all P. falciparum strains tested), 
these plants require agronomic improvement through se-
lection to increase biomass and genetic homogeneity for 
growth in the Amazonian ecosystems. In vitro testing 
for antiplasmodial activity is an important tool for qual-
ity control because the inhibition of P. falciparum by A. 
annua infusions is related, in general, to high levels of 
artemisinin and other antimalarial components to which 
these parasites are sensitive.
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